A recent study from the Botucatu School of Medicine at São Paulo State University (FMB-UNESP), Brazil, highlights the potential of low-dose vitamin D supplementation to significantly improve outcomes in breast cancer patients undergoing neoadjuvant chemotherapy. Involving 80 women aged over 45 with breast cancer, the randomized controlled trial divided participants into two groups: one receiving 2,000 IU of vitamin D daily and the other a placebo. All underwent standard neoadjuvant chemotherapy to shrink tumors prior to surgery. After six months, the vitamin D group showed a remarkable 43% rate of complete pathological response (complete cancer disappearance), compared to just 24% in the placebo group—a relative increase of 79% in treatment success. This difference was statistically significant despite the small sample size. Notably, baseline vitamin D levels were low in most participants (<20 ng/mL), aligning with common deficiencies observed in Indian populations due to limited sun exposure, dietary habits, and urban lifestyles. Supplementation effectively raised these levels during treatment, suggesting a supportive role in enhancing chemotherapy efficacy. Eduardo Carvalho-Pessoa, a study author and president of the São Paulo Regional Brazilian Society of Mastology, emphasized that this dosage is well below deficiency correction thresholds (e.g., 50,000 IU weekly) and poses minimal risk of toxicity, making it a safe, cost-effective adjunct compared to expensive chemosensitizing drugs often unavailable in public health systems like India’s Ayushman Bharat.

Vitamin D, primarily synthesized via sunlight and obtained from fortified foods, is crucial for calcium homeostasis and immune modulation, with emerging evidence linking it to anti-cancer effects through improved immune surveillance and reduced inflammation. This study builds on prior research but uses a modest dose, contrasting with high-dose trials, and underscores its accessibility for resource-limited settings in India, where breast cancer incidence is rising among women over 40. However, experts caution that while promising, these findings require validation through larger, multicenter trials to elucidate mechanisms—such as vitamin D’s influence on tumor microenvironment or drug metabolism—and optimal dosing for diverse populations. Indian oncologists should consider screening for vitamin D deficiency in breast cancer patients, as per guidelines from bodies like the Indian Council of Medical Research, recommending 600-800 IU daily for adults, while monitoring for hypervitaminosis symptoms like hypercalcemia. This approach could integrate seamlessly into holistic cancer care, potentially improving remission rates and quality of life without adding financial burden.